
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39251782
72082
10.1038/s41598-024-72082-y
Article
Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection
Li Xiaodan 1
Song Dongxu 1
Hao Yingxuan 1
Ren Mingjing 1
Guo Yanhong 1
Zhao Huayan 2
Wang Yulin 1
Tang Lin tanglin@zzu.edu.cn

1
1 https://ror.org/056swr059 grid.412633.1 Department of Nephropathy, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052 Henan China
2 https://ror.org/056swr059 grid.412633.1 Department of Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052 Henan China
9 9 2024
9 9 2024
2024
14 2098121 2 2024
3 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Rituximab occasionally induces reactivation of hepatitis C virus (HCV) in patients with resolved HCV infection, sometimes with fatal consequences. As rituximab has become one of the first-line therapies for the treatment of phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN) and is more widely used, there is a lack of studies reporting the effectiveness and safety of rituximab in patients with PLA2R-associated MN and resolved HCV infection. A single-center retrospective study was conducted on PLA2R-associated membranous nephropathy (MN) patients who were HCVAb positive but HCV-RNA negative and treated with rituximab. A total of 598 adult patients with PLA2R-associated MN who underwent rituximab therapy were screened. General clinical information, including gender, age, pathological data, and previous treatment plans, was collected from medical records. Routine blood tests, liver and kidney function assessments, blood lipid profiles, 24-h urine protein levels, anti-PLA2R antibody titers, circulating B-cell counts, and HCV viral loads were measured at the time of rituximab infusion and repeated at intervals of 1–3 months post-rituximab administration. A total of 8 patients were enrolled, with a median follow-up period of 19.00 (range: 16.00–25.25) months. Among the 8 patients, 5 were male, and the mean age was 50.13 ± 4.29 years. Histological findings indicated that tubuloreticular inclusions, mesangial deposits, intramembranous deposits, and subendothelial deposits were not observed in any of the 8 patients. The overall 1-year remission rate for these patients was 75%, accompanied by a significant reduction in proteinuria. Additionally, blood albumin levels increased significantly, and renal function remained stable. No increase in HCV viral load and stable liver function tests were observed throughout the entire follow-up period. This study suggested that on the basis of successful eradication of HCV virus with antiviral drugs, rituximab can effectively induce clinical remission of patients with PLA2R associated MN and resolved HCV infection, and does not lead to a significant increase in HCV virus load. However, this finding is based on a very small sample size and should be confirmed in larger clinical trials.

Keywords

PLA2R associated membranous nephropathy
Phospholipase A2 receptor
Resolved HCV infection
Rituximab
Subject terms

Kidney diseases
Outcomes research
http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 82200839 Tang Lin issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Hepatitis C virus (HCV) infection is a global health problem, with an estimated 71 million people chronically infected with HCV. In 2015, the global incidence of HCV was 23.7 cases per 100,000 population, and the estimated number of new diagnoses of HCV infection in 2015 was 17.5 million1. Despite the availability of effective anti-HCV drugs, there is a risk for reactivation of HCV in patients with resolved HCV infection with immunosuppressive therapy2,3.

It has been demonstrated that although rituximab greatly improved the prognosis of patients with hematological malignancies and rheumatoid arthritis, it is also associated with HCV reactivation4,5. Recently, rituximab has emerged as an effective treatment option for patients with phospholipase A2 receptor (PLA2R) associated membranous nephropathy (MN)6. However, despite the increasing use of rituximab, there is a lack of studies related to HCV reactivation in patients with PLA2R associated MN and resolved HCV infection receiving rituximab. With the increased use of rituximab in patients with PLA2R associated MN, there is an urgent need to determine the risk of HCV reactivation in these populations. Therefore, we included a group of patients with PLA2R associated MN in combination with resolved HCV infection treated with rituximab to determine the efficacy and safety of rituximab treatment in these patients, especially the risk of HCV reactivation.

Methods

Study design and patients

This is a retrospective study. A total of 598 adult patients with PLA2R associated MN who received rituximab at the First Affiliated Hospital of Zhengzhou University from January 2019 to December 2021 were screened. We identified 8 cases of PLA2R associated MN with resolved HCV infection. A diagnosis of resolved HCV infection was serum positivity with HCV RNA undetectable.

The exclusion criteria were as follows: (1) patients together with additional glomerular diseases including secondary membranous nephropathy; (2) patients who had poor follow-up compliance while receiving rituximab; (3) patients with a follow up period less than 12 months; (4) patients who were co-infection with hepatitis B virus; (5) patients who received other immunosuppressive agents except for rituximab simultaneously; (6) patients who are with cryoglobulinemia or hypocomplementemia. Informed consent was derived from the participants. Treatment regimens for all patients were based on the recommendations in relevant guidelines6. We also reviewed the guidelines about the study participants to confirm that our study was conducted in accordance with the relevant guidelines/regulations. The ethics committee of the First Affiliated Hospital of Zhengzhou University approved the study.

Immunosuppressive regimen and follow-up

The patients in this study all received a regimen of rituximab (375 mg/m2 × 4 doses or 1 g × 2 doses). RTX was redissolved in normal saline to a final concentration of 1 mg/mL, which was then infused at an initial rate of 20 mL/h, gradually increasing to 100 mL/h according to the tolerance of each patient. At 6 months, if the reduction in anti-PLA2R antibodies is between 50 and 90%, RTX therapy will continue.

General clinical information, including gender, age, , pathological information, and past treatment plans were gathered from medical records. Routine blood examinations, liver and kidney function tests, blood lipids, 24-h urine protein, anti-PLA2R antibody, circulating B-cell quantity, and HCV viral titers were collected at the time of rituximab infusion and repeated at 1–3 months interval after rituximab administration. According to age, gender, race, and serum creatinine levels, the estimated glomerular filtration rate (eGFR) was determined using the Chronic Kidney Disease Epidemiology Collaboration algorithm.

Definitions and monitoring of HCV reactivation

HCV reactivation was defined as the reappearance of HCV RNA after rituximab treatment. All patients were screened for HCV (HCVAb and HCV RNA) prior to rituximab treatment and monthly after receiving rituximab, along with routine liver function tests. Serum HCVAb was determined by electrochemiluminescence using the Cobase immunoassay analyzer and the immunoassay "ECLA" (Roche Diagnostic, Germany). Plasma HCV-RNA virus load was determined using real-time polymerase chain reaction on the ABI7500 Fluorescent Quantitative PCR Instrument (Applied Biosystems, USA). The lower limit of HCV RNA detection was 500 IU/mL in our study.

Treatment response

According to the 2021 Kidney Disease Improving Global Outcomes recommendations, complete remission was defined as urinary protein excretion < 0.3 g/24 h with normal serum albumin and serum creatinine. Partial remission was defined as proteinuria < 3.5 g/24 h or a reduction of ≥ 50% from peak, improvement or normalization of serum albumin, and stable serum creatinine. Immunologic remission was defined as the titer of anti-PLA2R antibody below 2 RU/ml.

Statistical analysis

Data was expressed as mean ± standard deviation, median, interquartile range, or percentages. Paired sample t-test or the Wilcoxon matched pair signed-rank (two samples) test was used for comparison between the two groups according to the distribution of data. The SPSS 24.0 software program was used for statistical analysis, and two-sided p-values were calculated.

Results

Baseline characteristics at rituximab infusion

There were 8 patients with PLA2R associated MN and resolved HCV infection who received rituximab treatment. The clinical characteristics of the patients at baseline was presented in Table 1. There were 5 male patients and 3 female patients, with a mean age of 50.13 ± 4.29 years old. Anti-PLA2R antibody was positive in all 8 patients. The baseline level of proteinuria was 5.29 (3.53, 6.51) g/24 h, serum albumin was 28.00 (25.05, 32.55) g/L, and eGFR was 71.10 (48.54, 89.97) ml/min/1.73 m2. According to the chronic kidney disease staging guidelines of Kidney Disease: Improving Global Outcomes, 2, 3, and 3 patients had stage 1, 2, and 3 chronic kidney disease, respectively.Table 1 Baseline characteristics of MN patients with HCV infection at RTX infusion.

Variables	All patients (n = 8)	
Demographics	
 Gender (male/female)	5/3	
 Age (year)	50.13 ± 4.29	
 Period of follow-up (months)	19.00 (16.00, 25.25)	
 Median time from the use of RTX to MN diagnosis (months)	16.00 (9.75, 39.50)	
 Median time from the use of RTX to HCV diagnosis (months)	58.50 (15.25, 90.75)	
 Median time from HCV diagnosis to MN diagnosis (months)	28.50 (0.00, 67.00)	
 Creatinine (µmol/L)	93.00 (79.00, 150.50)	
 eGFR (ml/min/1.73 m2)	71.10 (48.54, 89.97)	
 eGFR > 90	2	
 eGFR 60–89	3	
 eGFR 30–59	3	
 eGFR 15–29	0	
 eGFR < 15	0	
 Proteinuria (g/24 h)	5.29 (3.53, 6.51)	
 Albumin (g/L)	28.00 (25.05, 32.55)	
 Anti-PLA2R antibody titer (RU/mL)	34.20 (18.20, 85.30)	
 CD19 (/mm3)	292.00 (188.00, 327.75)	
 CD4 (/mm3)	558.50 (489.00, 1011.25)	
 Number (%) of patients with negative cryoglobulin test (N, %)	8 (100.00%)	
 Number (%) of patients with negative rheumatoid factor (N, %)	8 (100.00%)	
 C3 (g/L)	0.91 (0.84, 0.99)	
 C4 (g/L)	0.26 (0.23, 0.31)	
Number (%) of patients with, (N, %)	
 Hepatitis C occured before MN diagnosis	6 (75.00%)	
 Simultaneous diagnosis of MN and resolved hepatitis C	2 (25.00%)	
Number (%) of patients with, (N, %)	
 Relapse	5 (62.50%)	
 Ineffective	3 (37.50%)	
Previous therapies	
 Prednisone + cyclophosphamide, n	2	
 Prednisone + cyclosporine, n	1	
 Tacrolimus, n	8	
 Mycophenolate mofetil, n	0	
Data presented as median (first-third interquartile range) or mean ± SD or number (percentage). RTX, rituximab; MN, membranous nephropathy; HCV, hepatitis C virus; BP, blood pressure; eGFR, estimated glomerular filtration rate; anti- PLA2R antibody, anti-phospholipase A2 receptor antibody.

Following diagnosis by percutaneous renal biopsy, all patients were administered other immunosuppressant therapy before rituximab treatment, including cyclophosphamide combined with steroids in 2 patients, cyclosporine combined with steroids in 1 patient, and tacrolimus in 8 patients. The mean time from initial first-line immunosuppressive therapy to initial RTX therapy was 7.88 ± 4.67 months. In previous immunosuppressive treatment regimens, 5 patients achieved complete remission. However, during drug discontinuation or reduction, nephrotic syndrome relapsed. The other 3 patients did not achieve partial or complete remission of nephrotic syndrome in previous immunosuppressive treatment regimens.

Histological findings

All patients underwent kidney biopsy and were diagnosed with PLA2R associated MN. The renal biopsy findings are detailed in Table 2. LM showed a median of 33 glomeruli per biopsy (range 15–73). Interstitial fibrosis and tubular atrophy were present in 3 cases. Immunostaining revealed granular glomerular capillary wall positive for IgG and C3 in all patients. PLA2R and IgG4 staining was tested by renal biopsy staining and positive in all 8 cases. EM was performed in all patients and showed features of MN with subepithelial electron dense deposits. There were mostly Stage I-II and II-III and the remaining cases showed deposits of stage II. Tubuloreticular inclusions were not found in all patients. Mesangial, intramembranous, and subendothelial deposits were not seen in all 8 patients.Table 2 Pathological characteristics of patients.

No	PLA2R staining	Total glomeruli	Globally sclerotic glomeruli	IFTA (%)	IF	IgG4	EM stage	Subepithelial deposits	Intramembranous deposits	Subendothelial deposits	Mesangial deposits	TRIs	HCV load at renal biopsy	
1	Pos	24	0	0	IgG +  + , IgA ± , IgM-, C3 + , C4-, C1q-, FRA-	2 + 	I–II	Yes	No	No	No	No	Undetectable	
2	Pos	34	1	0	IgG +  + , IgA ± , IgM + , C3 +  + , C4-, C1q-, FRA-	2 + 	II–III	Yes	No	No	No	No	Undetectable	
3	Pos	15	0	0	IgG +  + , IgA-, IgM + , C3 + , C4 ± , C1q-, FRA-	1 + 	II	Yes	No	No	No	No	Undetectable	
4	Pos	43	0	10	IgG +  +  + , IgA-, IgM + , C3 + , C4-, C1q-, FRA-	2 + 	II–III	Yes	No	No	No	No	1.29 × 106 IU/ml	
5	Pos	73	0	25	IgG +  + , IgA-, IgM ± , C3 + , C4-, C1q-, FRA-	2 + 	II	Yes	No	No	No	No	Undetectable	
6	Pos	33	3	10	IgG +  +  + , IgA-, IgM + , C3 + , C4-, C1q-, FRA-	2 + 	I–II	Yes	No	No	No	No	Undetectable	
7	Pos	33	0	0	IgG +  + , IgA ± , IgM ± , C3 + , C4-, C1q-, FRA-	2 + 	II–III	Yes	No	No	No	No	Undetectable	
8	Pos	18	0	0	IgG +  + , IgA-, IgM-, C3 + , C4-, C1q-, FRA-	1 + 	I–II	Yes	No	No	No	No	Undetectable	
PLA2R, phospholipase A2 receptor; IFTA, interstitial fibrosis tubular atrophy; FRA, fibrin related antigen; EM, electron microscope; IF, immunofluorescence; HCV, hepatitis C virus; Neg, negative; Pos, positive.

Basic information of HCV infection

As shown in Table 3, in 5 patients, the diagnosis of HCV infection predated the renal biopsy, and in 3 patients the diagnosis of HCV infection and PLA2R associated MN was made at the same time. All 8 patients with previous HCV infection received antiviral agents and the load of HCV virus were undetectable at the time of rituximab treatment. None of the 8 patients had cryoglobulinemia and hypocomplementemia. (Table 1).Table 3 Clinical findings in MN patients with hepatitis C.

Cases	Sex	Age	Treatment of hepatitis C	Hepatitis C virus load at RTX infusion	Time from identification of resolved HCV infection to renal biopsy	Time from identification of resolved HCV infection to RTX infusion	Identification of resolved HCV infectionbefore/simultaneous MN diagnosis	
1	male	42	Sofosbuvir	Undetectable	14	91	Before	
2	Female	53	Sofosbuvir	Undetectable	74	90	Before	
3	Female	50	Sofosbuvir	Undetectable	43	51	Before	
4	Male	45	Ledipasvir and Sofosbuvir Tablets	Undetectable	0	15	Simultaneous	
5	Male	53	Peginterferon alfa-2a	Undetectable	195	241	Before	
6	Male	53	Elbasvir and Grazoprevir Tablets	Undetectable	0	16	Simultaneous	
7	Female	53	Ledipasvir and Sofosbuvir Tablets	Undetectable	46	66	Before	
8	Male	52	Ledipasvir and Sofosbuvir Tablets	Undetectable	0	6	Simultaneous	

Clinical and immunological outcomes

During the follow-up period of 19.00 (16.00, 25.25) months, the prevalence of patients with clinical remission increased from 0.00% at baseline to 50.00% (4/8), 75.00% (6/8), and 87.50%(7/8) at month 6, month 12, and last visit. The median CD19 + B cell count was 292/mm3 (IQR, 188.00 to 327.75) at baseline. CD19 + B cell counts at month 6 were significantly reduced compared with the baseline level (P = 0.017). At month 12 and the last visit, the number of CD19 + B cells had recovered to some extent. However, significant differences in CD19 + B cell counts remained between the baseline level and the levels at month 12 (P = 0.028) and the last visit (P = 0.018), respectively, after rituximab intervention (Table 4, Fig. 1).Table 4 Efficacy outcome variables.

Variables	Baseline	Month 6	Month 12	Last visit	
Remission, complete and partial (N, %)	NA	4 (50.00%)	6 (75.00%)	7 (87.50%)	
Remission, complete (N, %)	NA	2 (25.00%)	3 (37.50%)	5 (62.50%)	
Proteinuria (g/24 h)	5.29 (3.53, 6.51)	1.37 (0.46, 7.63)	1.10 (0.38, 1.85)a	0.62 (0.19, 0.91)a,b,c	
Albumin (g/L)	28.00 (25.05, 32.55)	35.20 (30.70, 40.00)a	42.30 (32.00, 44.30) a,b	42.30 (38.90, 43.50)a,b	
Serum creatinine (µmol/L)	93.00 (79.00, 150.50)	100.00 (89.25, 159.50)	95.00 (85.50, 150.50)	90.50 (83.00, 191.00)	
eGFR (ml/min/1.73 m2)	71.10 (48.54, 89.97)	55.83 (45.56, 86.69)	65.27 (46.81, 73.71)	67.24 (33.23, 79.90)	
Immunological remission (N, %)	NA	3 (37.50%)	6 (75.00%)	8 (100.00%)	
anti- PLA2R-Ab titer (RU/mL)	34.20 (18.20, 85.30)	6.60 (2.00, 18.00)a	2.00 (2.00, 2.50) a	2.00 (2.00, 2.00)a	
CD19 (/mm3)	292.00 (188.00, 327.75)	13.00 (0.00, 87.50)a	22.00 (8.50, 190.50)a	235.00 (45.00, 298.00)a	
Patients with undetectable hepatitis C virus (N, %)	8 (100.00%)	8 (100.00%)	8 (100.00%)	8 (100.00%)	
Data presented as number (percentage) or median (first-third interquartile range). aStands for p < 0.05 versus baseline; bStands for p < 0.05 vs month 6; cStands for p < 0.05 vs month 12. eGFR, estimated glomerular filtration rate; anti-PLA2R-Ab, anti-phospholipase A2 receptor antibody; CD, Cluster of differentiation.

Fig. 1 Serial levels of proteinuria (A), serum albumin (B), serum creatinine (C), eGFR (D), CD19 positive B cells (E), anti-PLA2R antibody (F), ALT (G), AST (H), and TBIL (I) after the rituximab treatment in all patients who had been followed up for a minimum of 12 months. The bars show median with interquartile range for each variable. ns P > 0.05 vs baseline; *P < 0.05 vs baseline; **P < 0.01 vs baseline; ***P < 0.001 vs baseline.

At month 6, month 12, and last visit, anti-PLA2R antibody titers [6.60 (2.00, 18.00) vs. 34.20 (18.20, 85.30) RU/ml, P = 0.059; 2.00 (2.00, 2.50) vs. 34.20 (18.20, 85.30) RU/ml, P = 0.028; 2.00 (2.00, 2.00) vs. 34.20 (18.20, 85.30 RU/ml, P = 0.018] were lower compared with the baseline levels (Table 4, Fig. 1). From baseline to month 6, month 12, and last visit, there was a decrease in prevalence of anti-PLA2R positive patients from 100.00% (8/8) to 50.00% (4/8), 12.50% (1/8), and 0.00% (0/0).

In term of proteinuria, the results showed that median levels of proteinuria were decrease from 5.29 (3.53, 6.51) g/d at baseline to 1.10 (0.38, 1.85) g/d at month 12 and 0.62 (0.19, 0.91) g/d at last visit, respectively (P = 0.041, P = 0.028). At month 6, serum albumin increased significantly [27.30 (20.20, 34.40) vs 23.70 (18.70, 25.70) g/L, P = 0.017] compared with the baseline levels. Continued improvements of serum albumin were observed between baseline and last visit (Table 4, Fig. 1).

Renal function was preserved since rituximab infusion in all patients demonstrated by serum creatinine and eGFR. This phenomenon also showed that the reduction of proteinuria caused by rituximab might maintain the stability of renal function to some extent (Table 4, Fig. 1).

Safety analysis of rituximab in patients with PLA2R associated MN and HCV infection

This study showed the safety of rituximab in patients with PLA2R associated MN and resolved HCV infection, which was demonstrated by no increase in HCV virus load and stable liver function tests after rituximab therapy (Fig. 1). During the follow-up, we also did not observe other adverse events including the occurrence of allergic reaction and infection.

Discussion

In this study, we retrospectively analyzed demographic characteristics, clinical remission rate, liver function and HCV load changes in patients with PLA2R associated MN and resolved HCV infection treated with rituximab.

Immunosuppression is known to increase HCV virus load and accelerate the progression of chronic HCV liver disease7–9, and previous studies suggested a similar risk with rituximab treatment10. This limited the application of rituximab in patients with PLA2R associated MN and resolved HCV infection. However, unlike HBV and HIV, HCV infection can be completely and permanently cured through antiviral therapy, as HCV does not have a long-term storage in the body. Furthermore, the widespread and effective application of antiviral drugs in clinical practice brings new hope to the application of rituximab in patients with PLA2R associated MN and resolved HCV infection in recent years.

At present, there are no studies about the safety of rituximab in patients with PLA2R associated MN and resolved HCV infection. However, in other diseases such as lymphoma and other HCV-associated nephritis, the results of the studies are inconsistent as to whether rituximab affects the replication of HCV. To date, in very small cohorts of patients with haematological malignancies receiving R-CHOP regimens, results had showed the elevated serum HCV virus load during or after rituximab-based chemotherapy11–13. In a larger cohort study of patients with HCV-associated diffuse large B-cell lymphoma14, serum HCV virus load increased significantly during rituximab-based chemotherapy and decreased significantly thereafter. There were also some studies similar to ours that confirm the safety of rituximab. A prospective controlled trial showed that among 31 patients with severe HCV associated cryoglobulinemia vasculitis who were randomly treated with rituximab and antiviral therapy, the complete remission rate of kidney disease was high and the safety was good15. Consistent with the above studies, other reports have shown the safety of rituximab in HCV infected individuals. These reports showed that there was no increase in HCV viremia after rituximab treatment, and liver function tests were stable16.

In our trial, we found no evidence of HCV reactivation . There were no significant changes in plasma viral levels over time and no biochemical evidence of hepatitis flare. Rituximab treatment was well tolerated, and no serious infections were detected. We considered that it may be related to the following reasons. Firstly, in the previous studies mentioned above, most of patients still had a high HCV virus load at rituximab infusion, and these patients also received cyclophosphamide, doxorubicin, vincristine, and prednisolone treatment when receiving rituximab treatment, which may be the reason for the increase of HCV virus load. In our study, patients received antiviral therapy before receiving rituximab treatment, and HCV virus was not detected at rituximab infusion. Moreover, in our study, patients did not receive other immunosuppressants except for rituximab, which may be one of the reasons why our results differ from some previous studies.

Our current study has several limitations. First, because the study was a retrospective study and the number of cases included in the study was low, our results should be interpreted with caution and should be further evaluated in a large study of prospective design. Second, due to the small sample size, we did not compare the difference in HCV viral load between patients treated with rituximab and those not treated with rituximab. Whether rituximab is an independent factor contributing to the increase of HCV viral load in patients with PLA2R associated MN is unknown and should be investigated in further studies.

In conclusion, our findings suggest that rituximab does not lead to a significant increase in HCV virus load in patients with PLA2R associated MN and resolved HCV infection. On the basis of successful eradication of HCV virus with antiviral drugs, rituximab may be an effective regimen for treating patients with PLA2R associated MN with resolved HCV infection. However, this finding is based on a very small sample size and should be confirmed in larger clinical trials.

Acknowledgements

Thanks to the support of Renal Pathology Laboratory, the First Affiliated Hospital of Zhengzhou University.

Author contributions

L.T. and X.D.L. designed the study. X.D.L. and Y.X.H. made the tables and figures, and wrote the manuscript. Y.X.H., H.Y.Z and Y.L.W collected the data. Y.H.G. and M.J.R. performed the statistical analysis. L.T. revised the manuscript. D.S. collected data, made statistical analysis and wrote the revised manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

Data availability

Data could be obtained upon request to the corresponding author.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Xiaodan Li and Dongxu Song.
==== Refs
References

1. Spearman C Dusheiko G Hellard M Sonderup M Hepatitis C Lancet 2019 394 1451 1466 10.1016/S0140-6736(19)32320-7 31631857
Spearman, C., Dusheiko, G., Hellard, M. & Sonderup, M. Hepatitis C. Lancet 394, 1451–1466 (2019).31631857 10.1016/S0140-6736(19)32320-7
2. Lee H Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy Gut and Liver 2017 11 870 877 10.5009/gnl16434 28750484
Lee, H. et al. Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy. Gut and Liver 11, 870–877 (2017).28750484 10.5009/gnl16434
3. Chen M Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy Lupus 2015 24 1029 1036 10.1177/0961203315571465 25691509
Chen, M. et al. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy. Lupus 24, 1029–1036 (2015).25691509 10.1177/0961203315571465
4. Lin K Lin J Tseng W Cheng T Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis J. Microbiol. Immunol. Infect. 2013 46 65 67 10.1016/j.jmii.2011.12.020 22627098
Lin, K., Lin, J., Tseng, W. & Cheng, T. Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis. J. Microbiol. Immunol. Infect. 46, 65–67 (2013).22627098 10.1016/j.jmii.2011.12.020
5. Nooka A Shenoy P Sinha R Lonial S Flowers C Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: A case report and review of literature Clin. Lymphoma Myeloma Leuk. 2011 11 379 384 10.1016/j.clml.2011.04.005 21729690
Nooka, A., Shenoy, P., Sinha, R., Lonial, S. & Flowers, C. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: A case report and review of literature. Clin. Lymphoma Myeloma Leuk. 11, 379–384 (2011).21729690 10.1016/j.clml.2011.04.005
6. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney international 100, S1–S276 (2021).
7. Soto B Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis J. Hepatol. 1997 26 1 5 10.1016/S0168-8278(97)80001-3 9147999
Soto, B. et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol. 26, 1–5 (1997).9147999 10.1016/S0168-8278(97)80001-3
8. Heneghan, M. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med. 335, 522; author reply 522–523 (1996).
9. Magy N Effects of corticosteroids on HCV infection Int. J. Immunopharmacol. 1999 21 253 261 10.1016/S0192-0561(99)00005-3 10408633
Magy, N. et al. Effects of corticosteroids on HCV infection. Int. J. Immunopharmacol. 21, 253–261 (1999).10408633 10.1016/S0192-0561(99)00005-3
10. Sansonno D Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20 Blood 2003 101 3818 3826 10.1182/blood-2002-10-3162 12506023
Sansonno, D. et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101, 3818–3826 (2003).12506023 10.1182/blood-2002-10-3162
11. Pitini V HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy Br. J. Haematol. 2010 150 116 118 10.1111/j.1365-2141.2010.08154.x 20230413
Pitini, V. et al. HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. Br. J. Haematol. 150, 116–118 (2010).20230413 10.1111/j.1365-2141.2010.08154.x
12. Coppola N Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 2012 44 49 54
Coppola, N. et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 44, 49–54 (2012).
13. Marignani M HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 2011 43 139 142
Marignani, M. et al. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 43, 139–142 (2011).
14. Ennishi D Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: A Japanese multicenter analysis Blood 2010 116 5119 5125 10.1182/blood-2010-06-289231 20823454
Ennishi, D. et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: A Japanese multicenter analysis. Blood 116, 5119–5125 (2010).20823454 10.1182/blood-2010-06-289231
15. Saadoun, D. et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 116, 326–334; quiz 504–325 (2010).
16. Sneller M Hu Z Langford C A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis Arthritis Rheumatism 2012 64 835 842 10.1002/art.34322 22147444
Sneller, M., Hu, Z. & Langford, C. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheumatism 64, 835–842 (2012).22147444 10.1002/art.34322
